MC4R is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Column chromatography takes a long time. Many manufacturers like Biotage, Buchi, Interchim and Teledyne Isco have developed automated flash chromatography systems that minimize human involvement in the purification process. Such systems are typically referred to as low pressure liquid chromatography (LPLC). They include components normally found on more expensive high pressure liquid chromatography (HPLC) systems such as a gradient pump, sample injection ports, a UV detector and a fraction collector to collect the eluent, but operating at a lower pressure (usually 350–525 kPa or 50.8–76.1 psi). Typically these automated systems can separate samples from a few milligrams up to an industrial many kilogram scale, and are cheaper and faster than doing multiple injections on preparative HPLC systems. The resolution (or the ability to separate a mixture) of an LPLC system is lower, as the packing material in an HPLC column can be much smaller, typically only 5 micrometre. This increases the stationary phase surface for interactions, and gives better separation. However, small packing media causes the high back pressure, thus "high pressure" liquid chromatography The LPLC columns are typically packed with silica of around 50 micrometres, thus reducing back pressure and resolution, but it also removes the need for expensive high pressure pumps. Manufacturers are now starting to move into higher pressure flash chromatography systems, which operate above 1 MPa (150 psi), calling them "medium pressure liquid chromatography" (MPLC).
An N-terminal KOW-like domain A central OB domain, which forms an oligonucleotide-binding (OB)-fold. It is not clear if this region is involved in binding nucleic acids A C-terminal domain which adopts an OB-fold, with five beta-strands forming a beta-barrel in a Greek-key topology Eukaryotes and archaea lack EF-P. In these domains, a similar function is performed by the archaeo-eukaryotic initiation factor, a/eIF-5A, which exhibits some modest sequence and structural similarity with EF-P. There are, however, important differences between EF-p and eIF-5A. (a) EF-P has a structure similar to that of L-shaped tRNA and it contains three (I, II and III) β-barrel domains. In contrast, eIF-5A contains only two domains (C and N) with a corresponding size difference. (b) Moreover, as opposed to eIF-5A, which contains the non-proteinogenic amino acid hypusine that is essential for its activity, EF-P displays a diversity of post-transcriptional modifications at the analogous position (β-lysylation of lysine residue, rhamnosylation of arginine residue, or none at all).
When compared to patients with type 2 diabetes, MODY patients are often more sensitive to sulphonylureas, such that a lower dose should be used to initiate treatment to avoid hypoglycaemia. Patients with MODY less often suffer from obesity and insulin resistance than those with ordinary type 2 diabetes (for whom insulin sensitizers like metformin or the thiazolidinediones are often preferred over the sulfonylureas).
== External links == The MEROPS online database for peptidases and their inhibitors: S01.218 Archived 2007-09-16 at the Wayback Machine Overview of all the structural information available in the PDB for UniProt: P04070 (Vitamin K-dependent protein C) at the PDBe-KB.
Sources: en.wikipedia.org
Hitler's impressions of the Roman Pantheon were revived when on June 24, 1940, he made a tour of selected buildings in Paris, with German architects Speer and Giesler and sculptor Arno Breker, including the Paris Panthéon, which seems to have disappointed him, independently recorded by Giesler and Breker. The sketch of the Volkshalle given by Hitler to Speer shows a traditional gabled pronaos supported by ten columns, a shallow rectangular intermediate block and behind it the domed main building. Giesler notes that the pronaos of the temple in Hitler's sketch is reminiscent of Hadrian's Pantheon and of the style of Friedrich Gilly or Karl Friedrich Schinkel. However, there was little about Speer's elaboration of the sketch that might be termed Doric, except perhaps for the triglyphs in the entablature, supported by the geminated red granite columns with their Egyptian palm-leaf capitals, previously employed by Speer in the portico outside Hitler's study on the garden side of the new Chancellery.
The heart has four valves, which separate its chambers. One valve lies between each atrium and ventricle, and one valve rests at the exit of each ventricle. The valves between the atria and ventricles are called the atrioventricular valves. Between the right atrium and the right ventricle is the tricuspid valve. The tricuspid valve has three cusps, which connect to chordae tendinae and three papillary muscles named the anterior, posterior, and septal muscles, after their relative positions. The mitral valve lies between the left atrium and left ventricle. It is also known as the bicuspid valve due to its having two cusps, an anterior and a posterior cusp. These cusps are also attached via chordae tendinae to two papillary muscles projecting from the ventricular wall. The papillary muscles extend from the walls of the heart to valves by cartilaginous connections called chordae tendinae. These muscles prevent the valves from falling too far back when they close. During the relaxation phase of the cardiac cycle, the papillary muscles are also relaxed and the tension on the chordae tendineae is slight. As the heart chambers contract, so do the papillary muscles. This creates tension on the chordae tendineae, helping to hold the cusps of the atrioventricular valves in place and preventing them from being blown back into the atria. Two additional semilunar valves sit at the exit of each of the ventricles. The pulmonary valve is located at the base of the pulmonary artery. This has three cusps which are not attached to any papillary muscles.
==== Cardiotoxins / Cytotoxins ==== Cardiotoxins are components that are specifically toxic to the heart. They bind to particular sites on the surface of muscle cells and cause depolarisation → the toxin prevents muscle contraction. These toxins may cause the heart to beat irregularly or stop beating, causing death. An example is the three-fingered cardiotoxin III from Chinese cobra, an example of the short three-fingered family (InterPro: IPR003572). Snake example: mambas, and some Naja species
Young's modulus can vary somewhat due to differences in sample composition and test method. The rate of deformation has the greatest impact on the data collected, especially in polymers. The values here are approximate and only meant for relative comparison.
Officials in the Truman administration placed responsibility for postwar tensions on the Soviets, claiming that Stalin had violated promises made at Yalta, pursued a policy of expansionism in Eastern Europe, and conspired to spread communism throughout the world. Historians associated with the "Wisconsin School" of diplomatic history such as Williams, however, placed responsibility for the breakdown of postwar peace mostly on the US, citing a range of US efforts to isolate and confront the Soviet Union well before the end of World War II. According to Williams and later writers influenced by his work—such as LaFeber, author of the popular survey text America, Russia, and the Cold War (published in ten editions between 1967 and 2006)—US policymakers shared an overarching concern with maintaining capitalism domestically. In order to ensure this goal, they pursued a policy of ensuring an "Open Door" to foreign markets for US business and agriculture across the world. From this perspective, a growing economy domestically went hand-in-hand with the consolidation of US power internationally. Williams and LaFeber also dismissed the assumption that Soviet leaders were committed to postwar "expansionism". They cited evidence that Soviet Union's occupation of Eastern Europe had a defensive rationale, and Soviet leaders saw themselves as attempting to avoid encirclement by the United States and its allies.
Sources: en.wikipedia.org
Controlling iron levels in the body is a critically important part of many aspects of human health and disease. There can be negative consequences on health if iron concentration is too high or too low.
=== Nucleation === The original theory from 1927 of nucleation in nanoparticle formation was Classical Nucleation Theory (CNT). It was believed that the changes in particle size could be described by burst nucleation alone. In 1950, Viktor LaMer used CNT as the nucleation basis for his model of nanoparticle growth. There are three portions to the LaMer model: 1. Rapid increase in the concentration of free monomers in solution, 2. fast nucleation of the monomer characterized by explosive growth of particles, 3. Growth of particles controlled by diffusion of the monomer. This model describes that the growth on the nucleus is spontaneous but limited by diffusion of the precursor to the nuclei surface. The LaMer model has not been able to explain the kinetics of nucleation in any modern system.
Employers can always voluntarily agree to collectively bargain, but if they do not, under section 237 the Fair Work Commission can require good faith bargaining after determining that there is majority support, "using any method the FWC considers appropriate", such as petitions, pledge cards, union lists, or in rare cases a ballot. Under section 228(1), the "good faith" requirements are that the FWC can make the employer and union meet at reasonable times, disclose relevant information, respond to proposals, genuinely consider them, refrain from capricious and unfair conduct, and recognise the other side's bargaining representatives. The employer is not required to make concessions or reach agreement on terms, but it was held in Endeavour Coal v Association of Professional Engineers, Scientists and Managers that the employer "must genuinely participate in the bargaining process; it cannot adopt the role of a distinterested suitor, only rejecting offers and proposals made by the other bargaining representatives." Here the employer refused to cooperate despite majority employee support for the union, and the FWC granted the APESMA an order (1) requiring a list of matters the employer was prepared to include in a bargain, and terms it would accept, (2) to cease unilaterally determining a standard form contract for staff, (3) to ensure someone with decision-making capacity attended meetings, (4) to meet within 21 days. The federal court partially upheld the award, saying that the FWC had not erred in finding a breach of good faith.
=== Regulation by keap1/nrf2/are pathway === External (via chemicals) and internal (stress response or caloric restriction) induction of NQO1 is mediated solely through the Keap1/Nrf2/ARE. Keap1 acts as the sensor which loses its ability to target Nrf2 for degradation upon exposure to the inducers. Nrf2 is consequently stabilized and accumulated in the nucleus upon which it binds to the AREs and initiates expression of cytoprotective genes including NQO1.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.